Department of Radiation Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, No. 420 Fuma Rd., Jin'an District, Fuzhou 350014, Fujian, China.
Clinical Oncology School of Fujian Medical University, No. 420 Fuma Rd., Jin'an District, Fuzhou 350014, Fujian, China.
Genet Res (Camb). 2023 Jul 18;2023:7129325. doi: 10.1155/2023/7129325. eCollection 2023.
Advanced glycation end products' receptor (AGER) is a multiligand receptor that interacts with a wide range of ligands. Previous studies have shown that abnormal AGER expression is closely related to immune infiltration and tumorigenesis. However, the AGER DNA methylation relationship between prognosis and infiltrating immune cells in LUAD and LUSC is still unclear.
AGER expression in pan-cancer was obtained by using the UALCAN databases. Kaplan-Meier plotter showed the correlation of mRNA expression levels and clinicopathological parameters. The protein expression levels for AGER were derived from Human Protein Atlas Database Analysis. The copy number, somatic mutation, and DNA methylation of AGER were presented with UCSC Xena database. TIMER platform and TISIDB website were used to show the correlation between expression and tumor immune cell infiltration level.
The expression level of was significantly reduced in lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC). Low expression of was significantly correlated with histology, stage, lymph node metastasis, and tumor protein 53 (TP53) mutation and could be used as a potential indicator of poor prognosis of LUAD and LUSC. Moreover, expression was positively correlated with the infiltrating immune cells. Further analysis showed that copy number variation (CNV), mutation, and DNA methylation were involved in AGER downregulation. In addition, we also found that hypermethylated AGER was significantly correlated with tumor-infiltrating lymphocytes.
AGER may be a candidate for the prognostic biomarker of LUAD and LUSC related to tumor immune microenvironment.
晚期糖基化终产物受体（AGER）是一种多配体受体，与广泛的配体相互作用。先前的研究表明，异常的 AGER 表达与免疫浸润和肿瘤发生密切相关。然而，LUAD 和 LUSC 中预后与浸润免疫细胞之间的AGER DNA 甲基化关系尚不清楚。
使用 UALCAN 数据库获取泛癌中的 AGER 表达。 Kaplan-Meier 绘图器显示 mRNA 表达水平与临床病理参数的相关性。从 Human Protein Atlas Database Analysis 获得 AGER 的蛋白表达水平。UCSC Xena 数据库展示了 AGER 的拷贝数、体细胞突变和 DNA 甲基化。TIMER 平台和 TISIDB 网站用于显示表达与肿瘤免疫细胞浸润水平之间的相关性。
在肺腺癌（LUAD）和肺鳞状细胞癌（LUSC）中， 的表达水平显著降低。低表达与组织学、分期、淋巴结转移和肿瘤蛋白 53（TP53）突变显著相关，可作为 LUAD 和 LUSC 预后不良的潜在指标。此外，表达与浸润免疫细胞呈正相关。进一步分析表明，拷贝数变异（CNV）、突变和 DNA 甲基化参与了 AGER 的下调。此外，我们还发现高甲基化的 AGER 与肿瘤浸润淋巴细胞显著相关。
AGER 可能是与肿瘤免疫微环境相关的 LUAD 和 LUSC 预后的候选生物标志物。
